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Abstract 
Background: In patients receiving dialysis, blood borne infections remains one of the most public causes of 
morbidity, hospitalization and death. Among dialysis patient’s long-term hemodialysis (HD) therapy, frequency 
of blood transfusions and multiple blood transfusions enhance the risk of acquiring blood-borne infections.  
Objective: The aim of the study was to identify predictors for HCV sero-conversion in HD patients.  Method: 
Prospective observational study was conducted on 173 CKD patients undergoing HD. Anti HCV antibody 
testing was accomplished at the start of study and every 2-3 months subsequently. To identify seroconversion, 
patients who were sero-negative for HCV were monitored. Results: Prospective follow-up exposed an 
occurrence of seroconversion of 12.1% during study duration. On multivariate analysis, both increase in the 
duration on hemodialysis besides attending more than one center for HD were significantly associated with anti-
HCV positivity (p < 0.05, OR 0.185), (p <0.05, OR 4.52) respectively. Risk factors blood transfusion and AST > 
40IU/L also shows significant association for seroconversion (p<0.05). Conclusion: It is concluded that increase 
post dialysis incidence of HCV occurs as specific guidelines for HCV infected patients were not followed. 
Regular surveillance for HCV infection helps dramatically in decreasing the spread of HCV in hemodialysis 
unit. 
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1. Introduction 
Hepatitis C virus (HCV) infection is substantial reason of morbidity and mortality in hemodialysis  patients [1, 
2] and observed as major public health problem [3, 4] infecting 170 million people globally [5]. Patients who 
undergo maintenance hemodialysis (HD) treatment are at high risk of getting infections and have a greater 
prevalence of HCV than the general population [6-9]. Preceding current screening of blood donors, blood 
transfusions was related with HCV infection essential to recover the anaemia related with kidney syndrome [10, 
11]. Multiple blood transfusions and prolonged vascular exposure increase the probability of getting blood-
borne infections in patients experiencing HD. Among end stage renal disease (ESRD) patients, blood borne 
virus is predominantly higher because of illicit drug use, inadequate sterilization of medical equipment, invasive 
dialysis procedures, mode of dialysis, contaminated blood and blood products and duration of end stage kidney 
disease [12-17]. Second most recurrent source of HCV infection is the nosocomial transmission [18, 19]. Most 
incidences of HCV transmission are consequently due to patient-patient transmission in the hospital setting 
through invasive procedures, such as sharing of multi dose vials, sharing of dialysis equipment, insertion of an 
intravascular catheter, surgery and colonoscopy [20-24]. Inadvertent bacteria transmission to patients through 
environmental surfaces, contact with contaminated HD equipment and supplies during treatment [25, 26], use of 
multi dose medication vials, regular use of recombinant human erythropoietin and staff members has been 
revealed as the most significant cause of HCV [27, 28]. With this background, the current study aims to 
determine the incidence and possible risk factors of HCV infection in renal disease patients undergoing HD in 
tertiary care hospital of Pakistan.  
2. Methodology 
2.1. Study setting 
This descriptive observational study was performed in HD center of a tertiary care hospital treating adult CKD 
patients from January to October 2018. 
2.2. Study design 
During study period, Step I of the study was to collect the cross-sectional facts in maintenance HD facility about 
all adult CKD patients. Patient demographics and medical information were attained from patient’s medical 
record such as patient’s age, gender, level of education, type and stage of kidney disease, HD period, therapeutic 
history and sero-positivity to HD along with laboratory results. HCV sero-positivity was termed as: 
identification of HCV antibodies by 3rd generation enzyme linked immunoassay (ELISA), carried out in limited 
laboratories. Furthermore, all CKD patients undergoing HD per shift were interviewed during study period 
about further probable risk factors for HCV infection. These comprised of associated comorbidity, status of 
anemia treatment, HCV status of sexual partner, history of blood transfusions (number and time of blood 
transfusion) and history of visits to another dialysis center for hemodialysis. Data related to infection control 
procedures was also obtained at HD unit.  During follow-up, Step II of the current study was to prospectively 
observe and identify seroconversion to HCV in already sero-negative patients. This step covered a cohort of 173 
CKD patients from a single tertiary care hospital. All seroconversions were documented and comprised whether 
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the patient was transplanted or expired. All HD patients were observed to guarantee the inclusion of every new 
seroconversion during the study duration and to approve the positive results; all new sero-conversions were 
retested.   
2.3. Ethical approval of study 
Permission to carry out the study was approved from the respective tertiary care center on their letter head and 
signed from respective authorities. The project was permitted by the Bio-Ethics Committee of research institute. 
Patients inclusion was made after a written informed consent. 
3. Statistical Investigation 
Information were accomplished and evaluated using SPSS version 2.1 (IBM). A multinomial logistic regression 
(MLR) model was used to investigate the possible predictors for HCV seroconversion. Study was emphasised 
on patients with seroconversion, that was compared to patients having no conversion in their status to classify 
the reasons causative of seroconversion throughout the HD treatment. Independent variables included number of 
blood transfusions, hemodialysis duration, number of altered hemodialysis units visited for cure and lab values 
of AST and ASTwere entered in the model. Alpha was fixed at 5% level. 
4. Results 
4.1. Influencing factors 
173 participants undergo hemodialysis during the study duration. The mean age of the HD patients included was 
46.4 years (SD ± 13.37) and the age range was 16 to 71 years. Among those 15.6 % of the patients were of 18-
30 years, 28.9 % of 31-45 years, 42.2 % of 46-60 years and 13.3 % of 61-75 years.  The highest numbers of 
ESRD incidences were seen in the patient with advanced age (46-60). Just over half (63.6%) of the participants 
were male and most (83.8%) married. Majority of people were those who suffer from chronic kidney disease 
have low education level (72.3%). Based on HD treatment duration, from which 13.3% undergoing HD from 3 
months and 86.7% from >3 months (ranging from three to 60 months). Study included those participants who 
were 100.0% HCV negative before the initiation of HD and all of the patients undergoing HD were of chronic 
renal failure. None of the patient was co-infected by HCV and HBV. Over half (56.6%, 98/173) of all patients 
had conventional blood transfusions and 50.9% (88/173) were known to have received management at different 
HD units.  Causes of ESRD included hypertension, diabetes mellitus and other unknown causes, among which 
(55.5%, 96/173) participants had two or less than two comorbid condition while (44.5%, 77/173) had more than 
two comorbidities. Table 1 illustrate the demographics of the studied people consequently. Study revealed that 
seroconversion occurred in 21 patients out of 173 patients (12.1%) among which 38.1% were of 31-45 years of 
age, majority of them were male (71.4%) and 85.7% were married, even though no variations were detected in 
HCV infection status of remaining 152 patients. Seroconversion was not considerably related with sexual 
characteristics and marital status of the patient. In age groups of the participants only 18-30 year of age showed 
significant association (p= 0.006, OR 0.095, CI 0.018-0.508) while advancing age proven to be a risk factor for 
seroconversion (p>0.05, OR 0.625, CI 0.053-7.32). 
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Table 1: Characteristics of hemodialysis patients and evaluation of factors associated with seroconversion 
during dialysis treatment by regression analysis (n=173) 
Patient medical 
information 
 HCV negative 
 
 
N (%) 
n = 152 
Seroconversion to 
HCV positive 
 
N (%) 
n = 21 
Multi logistic 
OR p-value 
Age groups  18-30 
31-45 
46-60 
61-75 
25(16.4) 
42(27.6) 
66(43.4) 
19(12.5) 
2(9.5) 
8(38.1) 
7(33.3) 
4(19.0) 
0.095 
0.625 
0.497 
0.997 
0.006  
0.708 
0.609 
0.998 
Gender  Male 
Female  
95(62.5) 
57(37.5) 
15(71.4) 
6(28.6) 
1.609 
. 
0.400 
. 
Marital status  Married 
Unmarried  
127(83.6) 
25(16.4) 
18(85.7) 
3(14.3) 
0.158 
. 
0.171 
. 
Education  Educated 
Uneducated  
43(28.3) 
109(71.7) 
5(23.8) 
16(72.6) 
0.332 
. 
0.165 
. 
Employment  Employed 
Unemployed  
15(9.9) 
137(90.1) 
5(23.8) 
16(72.6) 
5.556 
. 
0.036 
. 
Hemodialysis 
duration 
3 months 
>3 months 
23 (15.1) 
129 (84.9) 
7(33.3) 
14(66.7) 
0.629 
0.185 
0.434 
0.000 
Associated 
comorbidity 
<2 or 2 morbidities 
>2 morbidities 
85 (55.9) 
 
67 (44.1) 
11 (52.4) 
 
10 (47.6) 
0.939 
 
1.040 
0.129 
 
0.149 
Anaemia treatment Blood transfusion 
 
Erythropoietin 
treatment 
 
Blood transfusion & 
erythropoietin 
13 (8.6) 
 
 
 
74 (48.7) 
 
 
65 (48.2) 
3 (14.3) 
 
 
 
3 (14.3) 
 
 
15 (71.4) 
0.684 
 
 
 
0.150 
0.620 
 
 
 
0.006 
No. of Blood 
transfusions 
<5 or = 5 
>5 
34 (22.4) 
43 (28.3) 
5 (23.8) 
15 (71.4) 
0.147 
0.349 
0.000 
0.000 
Vaccination for 
hepatitis B 
 
No  
Yes  
52 (34.2) 
100 (65.8) 
6 (28.6) 
15 (71.4) 
0.121 
0.171 
0.152 
0.208 
Recent surgery 
 
 
 
No 
Yes 
 
131 (86.2) 
21 (13.8) 
7 (33.3) 
14 (66.7) 
0.113 
. 
0.000 
. 
Screening of blood 
donor 
Yes 
Don’t know 
No donor 
58 (38.2) 
19 (12.5) 
75 (49.3) 
9 (42.9) 
11 (52.4) 
1 (4.8) 
5.662 
21.33 
. 
0.121 
0.006 
. 
Family history of 
HCV  
Negative 
positive 
131 (86.2) 
21 (13.8) 
12(57.1) 
9 (42.9) 
0.443 
. 
0.173 
. 
History of medication 
use other than 
allopathic  
 
No  
Yes 
 
90 (59.2) 
 62 (40.8) 
 
8(38.1) 
13 (61.9) 
 
1.271 
. 
 
0.702 
. 
History of piercing 
and acupuncture 
No 
Yes  
137 (90.1) 
15 (9.9) 
17 (81.0) 
4 (19.0) 
0.939 
. 
0.933 
. 
HBV vaccine had been directed in 115 of 173 patients however post vaccination antibody levels were not tested. 
HBV immunization showed non-significant association with seroconversion status (p>0.05). Vaccination was 
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routinely practiced at the unit; 71.4% seroconverted patients were vaccinated. 
4.2. Risk Aspects for HCV infection 
With HCV seroconversion risk factors (vulnerable sexual interaction, inoculating drug use, history of recent 
surgery, sharing of toothbrush razor or blade used by barber and tattooing) were not considerably related. Out of 
21 seroconverted patients, 9 (42.9%) described to have HCV positive sexual companion. Since HCV spread 
through blood and blood products and blood transfusion is one of the most important possible factor in HCV 
transmission. In our present study, 15(71.4%) out of 21 seroconverted patients had received beyond 5 times of 
blood transfusion, remaining 23.8% were received less than 5 transfusions. Seroconversion was greater in 
patients with history of blood transfusion and seroconverted patients were considerably more probably have 
received greater number of blood transfusions ( P= 0.000,OR 0.349, 95% CI 0.194-0.628) and significantly 
more likely to have more than two altered HD units (P= 0.000, OR 4.52, CI 2.76-7.40) compared with HCV 
negative patients. 52.4% patients were unfamiliar about the effective screening of blood donor. Poor blood 
donor screening was observed as risk factor for HCV acquisition (p= 0.06, OR 21.3 CI 2.3-192.7).Based on the 
duration of HD, 14 (66.7%) out of seroconverted patients undergo HD for >3 months so the hemodialysis 
duration was significantly longer in patients with seroconversion (P= 0.000, OR 0.185, CI 0.08-0.38). As 
described in Table 2, a non-significant relationship(p>0.05) was detected among the hazard of seroconversion 
with a history of associated comorbidity ,piercing and acupuncture, history of medication use other than 
allopathic, as well as family history of HCV of study participants. After removing potential predictors such as 
cirrhosis, alcohol and herbal intake that can rise liver enzyme, higher levels of aspartate aminotransferase (AST) 
and alanine transaminase (ALT) were observed in 12.1% (21/173) of study participants. AST > 40 IU/L (P = 
0.000, OR 0.927, CI 0.889-0.967) and ALT > 56IU/L (p= 0.009, OR 1.051, CI 1.013-1.091) were associated 
with HCV positivity. 
Table 2: Association between AST, ALT and HCV infection 
 Continuous variables Binary logistic Multivariate 
 Mean ±S.D OR p-value OR p-value 
Dialysis from other 
centre 
-0.156± 0.945 3.210 0.000 4.523 0.000 
ALT levels 26.66 ±28.40 0.996 0.352 1.051 0.009 
AST levels 26.16 ±23.38 0.991 0.049 0.927 0.000 
5. Discussion 
The current study assessed HCV seroconversion in ESRD patients undergoing HD and its relationship with risk 
factors and facility specific practice patterns. In patients receiving HD treatment, the seroconversion rate for 
HCV infection and incidence of anti-HCV antibodies is remarkably significantly greater than the general 
population [16-29]. Our study reports that 21 seroconversions for HCV infection during study duration through 
eventual follow-up of sero negative HD patients providing a general incidence of 12.1% of total patients. In 
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Libya, similar high occurrence of new HCV infections was observed during 1 year surveillance period (7.2%) 
[6]. The prevalence rate of prevalence rate of seroconversion was found to be higher among men than women 
and in employed, older patients and it is correlated with literature [9]. One must proceed into consideration that 
this concluding study had a relatively less sample size (n=173) and all patients were recruited from a distinct 
HD center. Our study shows that ESRD patients of 18-30 years of age revealed significant association with 
seroconversion while greater incidence of HCV sero-positivity was observed in elder patients of age 31-75. On 
average older age prove to be a best predictor for acquiring HCV infection in patients undergo HD treatment. 
This observation is in agreement with other studies [30, 31].  Conversely HCV seroconversion was significantly 
associated with length of time on HD. Study participants undergo hemodialysis for longer duration was more 
prone towards HCVacquisition. It is dependable with nosocomial spread associated to dialysis; meanwhile 
extensive duration of dialysis treatment signifies a longer period at hazard of attaining an infection. Related 
observation have been stated by different authors [5]. Another study in 2006 showed that in HD patients the 
frequency of HCV was associated with longer period of HD therapy, this study also revealed that those HCV 
negative patients who have longer period of HD treatment became seroconverted. These outcomes are 
compatible with the findings of other studies [2]. It is of vital importance to prevent nosocomial transmission in 
Pakistan such as HCV antiviral treatment is costly, and its accessibility is restricted to only limited centers.   On 
the other hand ESRD patients require blood transfusion and erythropoietin  for anemia treatment [10], study 
revealed that patients receiving erythropoietin treatment only are less susceptible towards acquiring HCV 
whereas a progressive history of blood transfusions along with number of blood transfusions was identified as 
risk factor for HCV spread. Strong association of blood transfusion with HCV infection was reported by other 
studies [9, 32]. In transmission of HCV infection  through contaminated needles or syringes and blood 
transfusion, medical interventions play the most important role [18].  Poor screening of blood donors was 
documented as principal basis of HCV infection preceding to the institution of history of blood transfusions. Our 
study reported that a greater percentage of patients had formerly received blood transfusions without effective 
screening of blood donor (52.4%). In agreement with other studies HCV infection was further predominant in 
patients with poor screening of donor blood [6-19]. Moreover, it is probable that approximate blood donors 
infected with HCV are neglected by present screening measures and these might be essential for re-evaluation. 
Current study raised additional concern that there is a significant association of HCV infection with a history of 
HD from alternative centers. For social reasons, many patients travel but after starting dialysis some also moved 
to another dialysis center as an emergency providing acute services. HBV infection relationship with travel 
proposes the hazard of nosocomial infection during follow up of seroconverted patients. Other studies support 
this incidence [2, 6, 20]. These interpretations highlight the significance of separating patients following their 
return and observing them for seroconversion. In addition, history of recent surgery found to be more prominent 
in our study in seroconverted patients (66.7%) in comparison with sero negative group (13.8%). In the present 
study there was no association between seroconversion with history of renal transplantation, but we just found 
statistically significant relation with any recent surgical intervention of patients. These conclusions are 
compatible with the findings of other studies [5, 33].  On the other hand, the use of Multidose vials was mutual 
and is probable to have been an essential basis of nosocomial infections. Without being vaccinated against HBV 
many patients started HD treatment. Even the antibody level was not evaluated in vaccinated patients.  In 
seroconverted patients, mean values for Aspartate Aminotransferase and Alanine Aminotransferase were greater 
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in spite of being within the normal range. HCV infections are related with increased transaminase levels [10-
19]. Nevertheless in chronic dialysis patients with viral hepatitis infection, elevation of transaminases (>40 
IU/L) is not permanently exist [34]. We institute that AST > 40 show significant association with HCV 
infection. This recommends that an inexplicable or minor rise in AST could be used to indicate initial HCV 
seroconversion.As per the significant role of blood transfusion, behaviors like for each patient changing gloves 
after touching HD machines, paying careful attention to hand hygiene after contact with different patients, 
complete disinfection of HD machines, and declining the use of blood products to the minimum level are 
suggested to avoid transmission of blood borne infections. Some breaches in infection control practices were 
identified through investigation of local records. Particularly, the risk valuation was missing for prevention of 
infection and there were no explicit control measures for the dialysis facility as well as education and training of 
nursing staff were estimated inadequate. There were no written procedures for sterilization and cleaning of 
working surfaces and for safe direction of parenteral medication were missing. HCV infection was said to be 
scrutinized but there was no accessibility to written practices on HCV screening and on management of 
seroconverted patient. 
6. Study limitation 
Some boundaries of this study ought to be agreed. Repeatedly incomplete medical histories and further clinical 
facts was regularly attained by questioning HD staff and patients. In local laboratories serological analysis was 
performed and it is probable that there was variance in the quality of testing. To detect anti-HCV antibodies, 
HCV testing depend on a third generation ELISA and was not established by the finding of HCV RNA in blood 
samples. Genotyping or validation with PCR is presently not accessible in maximum centers.This study also 
reported that seroconversion was most likely to occur in patients undergo HD greater than three months Though, 
serologic assessments were not done frequently in every patient, consequently these outcomes are subjective as 
the infection might be done far ahead. 
7. Conclusion 
This study concluded that patients on continuous HD treatment have a high prevalence and incidence of HCV 
infection. Study revealed post dialysis occurrence of HCV within HD units. Vital action is required in HD 
centers to enhance and develop infection control actions and to diminish reliance on blood transfusions aimed at 
the management ofanemia. Regular surveillance for HCV infection helps significantly in decreasing the spread 
of HCV in HD unit. Poor practices of nursing staff and high level of non-adherence to infection control 
strategies were observed. Adherence of health care workers to infection control competencies can be improved 
by providing continuous education, supervision and monitoring 
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